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The steady-state airway epithelium has a low rate
of stem cell turnover but can nevertheless mount
a rapid proliferative response following injury. This
suggests a mechanism to restrain proliferation at
steady state. One such mechanism has been identi-
fied in skeletal muscle in which pro-proliferative
FGFR1 signaling is antagonized by SPRY1 to main-
tain satellite cell quiescence. Surprisingly, we found
that deletion of Fgfr1 or Spry2 in basal cells of the
adult mouse trachea caused an increase in steady-
state proliferation. We show that in airway basal
cells, SPRY2 is post-translationally modified in
response to FGFR1 signaling. This allows SPRY2 to
inhibit intracellular signaling downstream of other
receptor tyrosine kinases and restrain basal cell pro-
liferation. An FGFR1-SPRY2 signaling axis has previ-
ously been characterized in cell lines in vitro. We
now demonstrate an in vivo biological function of
this interaction and thus identify an active signaling
mechanism that maintains quiescence in the airway
epithelium.
INTRODUCTION
The airway epithelium of both mouse and humans is essentially
quiescent at steady state, with an extremely low rate of stem
cell proliferation (Cole et al., 2010; Kauffman, 1980; Teixeira
et al., 2013). Nevertheless, airway basal cells (BCs) can rapidly
enter the cell cycle in response to luminal cell loss (Hong et al.,
2004; Pardo-Saganta et al., 2015; Rawlins et al., 2007). Several
paracrine signaling pathways that promote airway stem cell
proliferation following injury have been characterized (reviewed
in Hogan et al., 2014). In addition, autocrine signaling mecha-
nisms can initiate airway proliferation in response to local
damage (Vermeer et al., 2003). A critical question remains:
are there are also mechanisms which actively inhibit airway
proliferation at homeostasis and therefore function to maintain
quiescence?This is an open access article undIn overall organization the mouse trachea is very similar to hu-
man smaller airways (Hackett et al., 2011; Rock et al., 2010; Teix-
eira et al., 2013). The adult mouse tracheal epithelium comprises
threemain cell types. BCs include both slowly dividing stem cells
and committed luminal precursors (Mori et al., 2015; Rock et al.,
2009; Watson et al., 2015). Luminal secretory cells can self-
renew and produce luminal ciliated cells, while ciliated cells are
terminally differentiated (Rawlins and Hogan, 2008; Rawlins
et al., 2007, 2009). In vitro and in vivo evidence suggests that
airway BC proliferation requires epidermal growth factor recep-
tor (EGFR) activity (Brechbuhl et al., 2014; You et al., 2002).
Moreover, inhibition of EGFR signaling via contact inhibition is
necessary to restrain BC proliferation following injury (Lu et al.,
2013). WNT and Notch signaling can also promote BC prolifera-
tion in some contexts (Giangreco et al., 2012; Paul et al., 2014;
Rock et al., 2011). By contrast, YAP prevents differentiation of
BCs (Mahoney et al., 2014; Zhao et al., 2014). However, no spe-
cific signaling pathways that actively inhibit BC proliferation at
steady state have been identified.
In other organs, stem cell quiescence is actively maintained by
feedback inhibition. For example, in the satellite cells of skeletal
muscle steady-state quiescence requires the function of specific
receptor tyrosine kinase (RTK) inhibitors, SPRY proteins, to
antagonize pro-proliferative fibroblast growth factor receptor 1
(FGFR1) signaling (Chakkalakal et al., 2012; Shea et al., 2010).
We speculated that similar mechanisms would operate in the
steady-state airway epithelium.
FGFR signaling has been extensively studied in lung develop-
ment and the smaller conducting airways (e.g., Abler et al., 2009;
Volckaert et al., 2011, 2013; Yin et al., 2011) where, similar to its
role in muscle, it has been found to have a pro-proliferative func-
tion. However, the role of FGFR signaling in airway BCs remains
undetermined. We therefore tested whether antagonism of
FGFR1 activity by SPRY proteins is required for BC quiescence.
Surprisingly, we found that deletion of either Fgfr1 or Spry2 re-
sulted in increased levels of BC proliferation. We demonstrate
that in airway BCs, SPRY2 is post-translationally modified down-
stream of FGFR1, allowing SPRY2 to antagonize signaling from
other RTKs, most likely EGFR, and maintain quiescence. There
is a well-documented in vitro relationship between FGFR1-medi-
ated modification of SPRY2 and RAS-ERK inhibition (Lao et al.,
2006, 2007). However, a role for this interaction has never previ-
ously been identified in vivo.Developmental Cell 37, 85–97, April 4, 2016 ª2016 The Authors 85
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Figure 1. Deletion of Fgfr1 in BCs Results in
Altered Tracheal Epithelial Homeostasis
(A) Relative expression of Fgfr1 and Spry2 mRNA in
sorted wild-type basal, secretory, and ciliated cells.
(B) Schematic of Fgfr1 conditional knockout exper-
iment.
(C) Relative expression of Fgfr1 mRNA in sorted
GFP+ BCs from control and Fgfr1 cKOmice 3weeks
after tmx administration.
(D) Representative confocal sections from control
Tg(KRT5-CreER);Rosa26RfGFP/+ and cKO Tg(KRT5-
CreER); Rosa26RfGFP/+; Fgfr1D/fx tracheae. Green,
GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei).
Increased labeling of luminal cells is visible in the
Fgfr1 cKOs by 5 weeks (arrowheads), becoming
large patches of labeled cells (brackets) by 13 and
24 weeks.
(E) Percentage of the total T1a+ BCs that are also
GFP+.
(F) Percentage of total T1a luminal cells that are
also GFP+.
Error bars denote SEM. Scale bars, 50 mm. See also
Figures S1 and S2.RESULTS
FGFR1 Signaling Is Required for Normal Tracheal
Cellular Homeostasis
FGFR signaling pathway components are readily detected in the
steady-state adult mouse trachea by RT-PCR (Figure S1A). Fgfr1
and Spry2 mRNA were also detected in purified BC, secre-
tory, and ciliated cell populations by qRT-PCR (Figures 1A,
S1B, and S1C) and by single-cell qRT-PCR (Watson et al.,
2015). Moreover, FGFR1 protein and mRNA were detected in
BCs and luminal cells in the intact mouse trachea (Figures S1D
and S1F). We conditionally deleted Fgfr1 and activated a GFP
reporter in tracheal BCs using Tg(KRT5-CreER); Rosa26R-
fGFP; Fgfr1D/fx (Fgfr1 conditional knockout, cKO) and control86 Developmental Cell 37, 85–97, April 4, 2016Tg(KRT5-CreER); Rosa26R-fGFP mice.
Four doses of tamoxifen (tmx) were admin-
istered to adult (>8 weeks old) mice (Fig-
ure 1B). To confirm deletion of Fgfr1fx in
the GFP+ BCs, we performed qRT-PCR
on pools of isolatedGFP+BCs and showed
that the level of Fgfr1 mRNA in the Fgfr1
cKOs was reduced to 20% of the control
level (Figure 1C). This result showed
that widespread co-recombination of the
Fgfr1fx and Rosa26RfGFP loci was occur-
ring, and we used GFP+ cells as a surro-
gate marker for Fgfr1D/D cells in further
experiments. However, it is important to
note thatRosa and Fgfr1 co-recombination
is 80%, and we therefore underestimate
the extent of the Fgfr1 phenotype using
this scoring method.
Tracheae were harvested at intervals
and processed for histology to assess
the contribution of GFP+, Fgfr1D/D BCs to
the epithelium during normal homeostaticturnover. At 1.5 weeks after tmx administration, 30% of total
BCs were GFP+ in both Fgfr1 cKOs and controls. In control
animals this percentage increased modestly to 40%–50% at
5–13 weeks after tmx administration, before dropping to initial
levels by 24 weeks. This change was much more marked in
the Fgfr1 cKO mice, in which the percentage of labeled BCs
peaked at 60% at 13 weeks before returning to initial levels (Fig-
ures 1D and 1E). In both genotypes, labeled BCs produced
labeled luminal cells as expected. However, luminal cell produc-
tion was greater in the Fgfr1 cKO mice, with levels of GFP+
luminal cells reaching 38% ± 2% of the total luminal cell popula-
tion by 24 weeks, compared with 21% ± 4% in the controls (Fig-
ure 1F). Tg(KRT5-CreER); Rosa26R-fGFP; Fgfr1+/fx (Fgfr1 condi-
tional heterozygous) mice displayed a phenotype similar to that
Figure 2. Loss of FGFR1 Signaling Results in
Increased Levels of BC Proliferation
(A) Representative confocal sections from control
Tg(KRT5-CreER);Rosa26RfGFP/+andcKOTg(KRT5-
CreER);Rosa26RfGFP/+; Fgfr1D/fx tracheae at 1.5 and
13 weeks after tmx administration. Green, GFP (re-
porter); red, KI67 (proliferating cells); white, KRT5
(BCs); blue, DAPI (nuclei). Arrowheads indicate
KI67+ cells.
(B) Percentage of GFP+ cells that co-express KI67.
(C) Relative expression of Ki67 mRNA in sorted
GFP+ BCs from control and Fgfr1 cKO mice
3 weeks after tmx administration.
(D) Schematic of in vitro experiment.
(E) Low-titer Ad-Cre infection induces sporadic
recombination in control Rosa26RfGFP/+ and cKO
Rosa26RfGFP/+; Fgfr1D/fx BCs. Green, GFP (re-
porter); blue, DAPI (nuclei).
(F) Fgfr1 deletion in vitro results in increased BC
proliferation. Red, KI67 (proliferating cells); blue,
DAPI (nuclei).
(G) Percentage of proliferating (KI67+) cells in vitro.
(H) Schematic for in vitro experiment. Wild-type
(WT) BCs plated at low density (3 3 104 cells/
insert) and exposed to 100 ng/ml FGF2 from day 2.
(I) FGF2-treated and control wild-type BCs at day 4
after plating. Red, E-cadherin (lateral cell mem-
brane); blue, DAPI (nuclei).
(J) Number of DAPI+ cells per colony in control and
FGF2-treated cells.
Error bars denote SEM, Scale bars represent
50 mm in (A), (E), and (F), and 20 mm in (I). See also
Figure S2.of the cKOs (Figures S2A and S2B). Thus, greater numbers of
both basal and luminal cells are produced by the Fgfr1D/D BCs
than controls, showing that FGFR1 signaling influences the
rate of epithelial cell turnover in the steady-state trachea.
Increased Levels of Basal Cell Proliferation in the Fgfr1
cKO Tracheae
Weassessedproliferation rates usingKI67antibody staining. This
showed that in vivo rates of proliferationwere>3-fold higher in the
Fgfr1D/D BCs than in controls (Figures 2A and 2B). Moreover, the
level ofKi67mRNA inGFP+BCs isolated fromFgfr1 cKO tracheaeDevwas increased11-fold comparedwithcon-
trols (Figure 2C). Proliferation levels were
intermediate in the Fgfr1 conditional het-
erozygotes (Figure S2C). We confirmed
the increase in BC proliferation in vitro us-
ing a limiting dose of Cre recombinase
adenovirus (Ad-Cre) to induce recom-
bination in small numbers of cells from
Rosa26R-fGFP; Fgfr1D/fx and control
Rosa26R-fGFP tracheae (Figure 2D). The
Fgfr1D/D cells produced larger GFP+ col-
onies than the controls, and these cultures
also contained higher numbers of KI67+
cells (Figures 2E–2G).
We predicted that if deletion of Fgfr1 re-
sults in BC proliferation, activating FGFR1signaling in vitro would inhibit growth of BC colonies. FGF2 is ex-
pressed in the homeostatic trachea (Figure S1A), is known to
activate FGFR1 preferentially in vitro, and is strongly linked to
FGFR1 activation in multiple in vivo situations (Arai et al., 2015;
Chakkalakal et al., 2012; Garmy-Susini et al., 2004; Hackett
et al., 2011; Hadjab et al., 2013; Kranenburg et al., 2005; Ornitz
et al., 1996). We therefore tested the effects of the addition of
exogenous FGF2 protein on the proliferation of wild-type primary
BCs in culture. We plated wild-type BCs at low density and
added FGF2 on culture day 2 after colonies had become estab-
lished (Figure 2H). As predicted, addition of FGF2 had theelopmental Cell 37, 85–97, April 4, 2016 87
Figure 3. Loss of FGFR1 Signaling in BCs Leads to an Increase in Phosphorylation of DownstreamEffector Proteins and aDecrease in Levels
of a SPRY2 Isoform
(A) Schematic of in vitro experiment.
(B) Representative western blots from control and Fgfr1 cKO day-5 BCs showing pERK1/2, total ERK1/2, pAKT, total AKT, SPRY2, and histone H3.
(C) Quantification of protein in (B).
(D) Model. A major function of FGFR1 in BCs is to post-translationally modify SPRY2, resulting in a SPRY2 isoform which can negatively regulate the ERK/MAPK
and AKT/PI3K pathways downstream of other RTKs.
(E) Confocal images of control Tg(KRT5-CreER); Rosa26RfGFP/+ and cKO Tg(KRT5-CreER); Rosa26RfGFP/+; Fgfr1D/fx tracheal sections at 1.5 weeks after tmx
administration showingan increase inpERK1/2 levels in theFgfr1 cKOBCs.Green,GFP (reporter); red, pERK1/2 (activeERK1/2); blue,DAPI (nuclei). Scale bar, 25mm.
(legend continued on next page)
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opposite effect to removal of Fgfr1 and significantly reduced col-
ony size (Figures 2I and 2J).
Fgfr1D/D BCs Have Increased Levels of MAPK and AKT
Pathway Activity
To identify the mechanism by which FGFR1 influences BC prolif-
eration, we assessed the levels of activity of well-characterized
downstream intracellular signaling pathways. Given that we
had successfully replicated the proliferation phenotype in pri-
mary cell culture (Figures 2D–2F), we used primary cultures of
Fgfr1D/fx cells with a high dose of Ad-Cre and harvested cells
3 days after infection for western analysis of the whole cell lysate
(Figure 3A). Genotyping of the cultures suggested that many
cells were Fgfr1D/D in these conditions (Figure S3A). These ex-
periments showed that there was a 2.2-fold increase in levels
of phosphorylated ERK1/2 in the Fgfr1D/D cells. In addition, there
was a 3.8-fold increase in total AKT protein and a 1.3-fold in-
crease in the fraction of phosphorylated AKT (Figures 3B and
3C). The change in MAPK pathway activity was confirmed in vivo
by immunostaining for pERK1/2, which showed higher levels in
Fgfr1D/D BCs than controls at 1.5 weeks after tmx administration
(Figure 3E). Thus, the loss of an RTK surprisingly resulted in
increased levels of signaling through the RAS-ERK and PI3K
intracellular pathways, which are typically associated with active
RTK signaling. We therefore analyzed negative regulators of
these signaling cascades. SPRY2 is a well-known transcriptional
target of FGFR signaling and has previously been shown to
be post-translationally modified downstream of FGFR1 activity
in vitro (Lao et al., 2007; Rubin et al., 2005). Two isoforms of
SPRY2 can be separated on polyacrylamide gels. Levels of the
faster-migrating (lower) isoform have been shown in vitro to in-
crease following FGFR1 activation. In addition, this isoform has
a greater ability to bind to GRB2 in vitro and has been proposed
to be the active isoform for inhibition of RAS-ERK signaling (Lao
et al., 2007). Interestingly, in the Fgfr1D/D cells there was a 2.2-
fold decrease in levels of the faster-migrating (lower, active for
ERK/AKT inhibition) SPRY2 isoform and a 1.3-fold increase in
levels of the slower-migrating (upper, unable to inhibit ERK/
AKT) isoform (Figures 3B and 3C). This suggests that a wild-
type function of FGFR1 signaling in the tracheal BCs is to modu-
late SPRY2 activity post-translationally, thus altering the ability
of SPRY2 to inhibit signaling downstream of other RTKs
(Figure 3D).
There is a strong connection between EGFR signaling and
airway BC proliferation (Brechbuhl et al., 2014). We tested the
hypothesis that because the Fgfr1 cKO BCs have more consti-
tutive activity of the ERK/AKT pathways, they would be more
resistant to EGFR inhibition than controls. We grew Fgfr1 cKO
and control BCs in the presence of 0.25 mM of the EGFR inhib-
itor erlotinib (Figure S4A). This resulted in a >5-fold decrease in
proliferation rates in the control cells, versus a 2-fold decrease
in the Fgfr1 cKO cells (Figures S4B–S4D). Moreover, levels of
EGFR protein were unchanged in the Fgfr1 cKO cells (Fig-(F) Schematic for exposure of wild-type BCs to FGF2.
(G) Representative western blots from day-6 FGF2-stimulated and control BCs s
(H) Quantification of protein levels in (G).
Error bars denote SEM. See also Figures S3–S5.ure S4E). The Fgfr1 cKO BCs are thus more resistant to EGFR
inhibition, supporting the hypothesis that the downstream
signaling pathways (ERK/PI3K) are more constitutively active
in these cells.
Stimulating BCs with FGF2 Results in Increased Levels
of the Faster-Migrating SPRY2 Isoform
We tested whether activating FGF signaling is sufficient to
modulate levels of the SPRY2 isoforms in wild-type cells (Fig-
ure 3F). A 10-min or 24-hr FGF2 stimulation resulted in a repro-
ducible small decrease in pERK1/2 compared with control cells,
particularly at the 10-min harvest time (Figures 3G, 3H, and
S5A–S5C). Following FGF2 stimulation we observed no change
in total SPRY2 levels but a 1.6-fold increase in levels of the
faster-migrating SPRY2 isoform (Figures 3G and 3H). These
changes never reached statistical significance. However, the
experiments were performed in primary cells that have multiple
inputs into the ERK pathway in the presence of serum and
the data were reproducible, supporting our hypothesis that
manipulating FGFR1 signaling results in post-translational
changes in SPRY2.
Fgfr1D/D BCs Cannot Produce Ciliated Cells
It has previously been reported that FGFR1 signaling in zebra-
fish and Xenopus embryos can regulate cilia assembly and
length (Hong and Dawid, 2009; Neugebauer et al., 2009). We
therefore examined ciliogenesis in the Fgfr1 cKO tracheae. At
24 weeks after tmx administration, Fgfr1 cKO tracheae had an
excess of GFP+ secretory cells and fewer GFP+ ciliated cells
than the controls (Figures 4A and 4B), suggesting that ciliated
cell production was impaired in the mutant. Indeed, the only
GFP+ ciliated cells that could be detected in the Fgfr1 cKO tra-
chea still retained FGFR1 protein (Figures 4A and 4C), indicating
that they were derived from Fgfr1D/fx cells, which had under-
gone partial recombination to activate the Rosa reporter but
had not deleted the Fgfr1fx allele. Based on scoring the percent-
age of luminal GFP+ cells that retained detectable FGFR1 pro-
tein in these samples, we were able to estimate the rate of
co-recombination of the two floxed alleles as 84% ± 2% (Fig-
ure 4C), in good agreement with our qRT-PCR-based estimate
(Figure 1C).
To assess the stage at which ciliated cell differentiation was
blocked in the Fgfr1 cKO cells, we stained tracheal sections
for the transcription factor FOXJ1, which is expressed during
ciliated cell differentiation and has a role in basal body
anchoring (Blatt et al., 1999; Huang et al., 2003). In the Fgfr1
cKO tracheae the number of GFP+, FOXJ1+ cells was signifi-
cantly decreased, confirming an early block in ciliated cell differ-
entiation (Figures 4B and 4D). These data suggest that in the
Fgfr1 cKO tracheae, luminal cell fate choice is disrupted and
secretory cells are produced at the expense of ciliated cells.
This phenotype is somewhat different to the published role for
FGFR1 in controlling cilia length in multi-ciliated cells in thehowing SPRY2, pERK1/2, total ERK1/2, pAKT, total AKT, and histone H3.
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Figure 4. Loss of FGFR1 Signaling Results in
a Block in Ciliated Cell Differentiation
(A) Confocal image of Tg(KRT5-CreER);
Rosa26RfGFP/+; Fgfr1D/fx tracheal section. Green,
GFP (reporter); blue, FGFR1; red, SCGB1A1 (secre-
tory cells); white, acetylated tubulin (ACT, cilia). In the
patch of GFP+ cells marked by the dashed bracket,
FGFR1 is absent and there are no ciliated cells. In the
GFP+ cells within the solid bracket, FGFR1 has not
beendeleted, thereare fewerGFP+cells, andciliated
cell differentiation has occurred.
(B) Percentage of GFP+ cells that co-express
SCGB1A1, ACT, or FOXJ1 in control Tg(KRT5-
CreER);Rosa26RfGFP/+; Fgfr1+/fx and cKO Tg(KRT5-
CreER); Rosa26RfGFP/+; Fgfr1D/fx animals 24 weeks
after tmx administration.
(C) Percentage of GFP+ luminal cells in cKO
Tg(KRT5-CreER); Rosa26RfGFP/+; Fgfr1D/fx trachea
that retain FGFR1 protein 24 weeks after tmx
administration.
(D) Sections from control and Fgfr1 cKO tracheae
at 24 weeks after tmx administration. Green,
GFP (reporter); red, g-tubulin (basal bodies); white,
FOXJ1 (ciliated cells).
(E) Schematic of in vitro experiment.
(F) Day-11 ALI cultures grown from control and
Fgfr1 cKO animals. Green, GFP (reporter); red, ACT
(cilia); blue, DAPI (nuclei).
Error bars denote SEM. Scale bars represent
100 mm in (A) and (F), and 50 mm in (D).zebrafish and Xenopus systems (Hong and Dawid, 2009; Neu-
gebauer et al., 2009). This may be a true cross-species differ-
ence or may reflect the limitations of the different experimental
systems used.
Homeostatic production of new ciliated cells occurs at an
extremely slow rate in vivo (Rawlins and Hogan, 2008). To
confirm the ciliated cell differentiation phenotype in the Fgfr1D/D
cells, we grew air-liquid interface (ALI) epithelial cultures from
Rosa26R-fGFP; Fgfr1D/fx and control Rosa26R-fGFP; Fgfr1+/fx90 Developmental Cell 37, 85–97, April 4, 2016tracheae and deleted the floxed alleles us-
ing Ad-Cre (Figure 4E). All control cultures
had robust differentiation of ciliated cells,
based on acetylated tubulin (ACT) localiza-
tion, but ciliated cells were not observed in
the Fgfr1 cKO cultures (Figure 4F).
In summary, the Fgfr1 cKO BCs have an
increased proliferation rate from 1.5 weeks
after injection. They are also unable to
produce mature ciliated cells, likely due
to a fate-choice defect. We focused on
BC proliferation as the primary phenotype
and, based on our observation that levels
of the fast-migrating SPRY2 isoform
were decreased in the Fgfr1 cKO cells
(Figures 3B and 3C), we hypothesized
that a major role of FGFR1 signaling in
the tracheal BCs is to modulate SPRY2
activity and, moreover, that the function
of SPRY2 in these cells is to inhibit
signaling activity downstream of RTKsother than FGFR1, for example EGFR, which is necessary for
tracheal BC proliferation (Brechbuhl et al., 2014; Lu et al.,
2013). To test this hypothesis, we deleted Spry2 in BCs of the
adult mouse trachea.
Loss of Spry2 Results in Increased Levels of Tracheal
Basal Cell Proliferation
Spry2 is widely expressed in basal and luminal cells of the ho-
meostatic mouse trachea (Figures 1A and S1). We generated
Figure 5. Deletion of Spry2 in BCs Results in
Increased Rates of Proliferation
(A) Schematic of Spry2 conditional knockout
experiment.
(B) Representative confocal sections from control
Tg(KRT5-CreER);Rosa26RfGFP/+andcKOTg(KRT5-
CreER); Rosa26RfGFP/+; Spry2D/fx tracheae. Green,
GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei).
Brackets indicate patches of labeled cells, more
prominent in the Spry2 cKO.
(C) Percentage of the total T1a+ BCs that are also
GFP+.
(D) Percentage of the total T1a luminal cells that
are also GFP+.
(E) Representative confocal sections from control
and cKO tracheae at 1.5 and 13 weeks after tmx
administration. Green, GFP (reporter); red, KI67
(proliferating cells); white, KRT5 (BCs); blue, DAPI
(nuclei). Arrowheads indicate KI67+ cells.
(F) Percentage of GFP+ cells that co-express KI67.
(G) Confocal z projections from sections of control
and Spry2 cKO trachea. Green, GFP (reporter);
red, KRT5 (BCs); white, E-cadherin (lateral cell
membranes); blue, DAPI (nuclei).
Error bars denote SEM. Scale bars represent
50 mm in (B) and (E), and 10 mm in (G). See also
Figure S6.Tg(KRT5-CreER); Rosa26R-fGFP; Spry2D/fx (Spry2 cKO) and
control Tg(KRT5-CreER); Rosa26R-fGFP adult mice and admin-
istered tmx to activate GFP and delete Spry2 in a subset of BCs
(Figure 5A). During normal turnover there was an increase in the
proportion of GFP+, Spry2D/D BCs compared with GFP+,
Spry2+/+ controls (Figures 5B and 5C). At the same time the pro-
portion of GFP+, Spry2D/D luminal cells also increased (Figures
5B and 5D). These changes most likely resulted from the
4-fold increase in rates of BC proliferation observed in the
Spry2 cKOs compared with controls (Figures 5E and 5F).DevThe proliferation phenotypes were thus
very similar between the Fgfr1 and
Spry2 cKO tracheae, supporting a strong
connection between the two proteins.
However, unlike the Fgfr1 cKO, no ef-
fects on ciliated cell differentiation were
observed in the Spry2 cKO tracheae (Fig-
ures S6A and S6B), suggesting that the
function of FGFR1 in luminal fate choice
is SPRY2 independent. In addition, in
contrast to Fgfr1, no phenotypes were
observed in Spry2 conditional heterozy-
gous tracheae (data not shown).
The Spry2 cKO cells were packedmore
tightly than control cells in the epithelium
(at 13 weeks after tmx administration
there were 16 ± 1.3 cells per 40 mm in
the control tracheal epithelia versus
23.7 ± 1.6 cells per 40 mm in the Spry2
cKOs; p = 0.01; Figure 5B), consistent
with the significantly increased prolifera-
tion rate. However, therewas no evidenceof epithelial stratification, and levels of E-cadherin protein (Fig-
ure 5G) and apical-basal polarity (Figure S6C) appeared normal.
These data suggest that the observed change in cell density may
result from an altered threshold for contact inhibition in the Spry2
cKO cells.
We tested whether we could recapitulate the Spry2 cKO phe-
notypes using Ad-Cre in primary tracheal cell culture (Figure 6A).
Deletion with a high titer of Ad-Cre resulted in loss of all detect-
able SPRY2 protein (Figure 6E) and failure to amplify the Spry2fx
allele from the genomic DNA (Figure S3B), suggesting that weelopmental Cell 37, 85–97, April 4, 2016 91
Figure 6. Rapidly Proliferating Spry2 Conditional Knockout BCs Have Elevated Levels of RAS-ERK and PI3K Signaling
(A) Schematic of in vitro experiment.
(B)Spry2 cKO (Rosa26RfGFP/+;Spry2D/fx) cells proliferatemore rapidly than controls (Rosa26RfGFP/fGFP) in vitro and aremore densely packed at culture day 5. Note
that not all cKO cells are GFP+, even though SPRY2 protein is undetectable. Green, GFP (reporter); red, KRT5 (BCs); blue, DAPI (nuclei). Arrowheads indicate
similar regions of the cultures.
(C) Spry2 cKO cells still undergo some contact inhibition in vitro at day 7 after ALI induction. Their proliferation rate slows following induction of ALI and there are
no regions of multi-layering, although KI67+ cells are still visible (arrowhead). Green, GFP (reporter); red, KI67 (proliferating cells); blue, DAPI (nuclei).
(D) Spry2 cKO primary cells continue to proliferate faster in vitro following passage at day 2 after replating. Green, GFP (reporter); red, KI67 (proliferating cells, e.g.
arrowhead); blue, DAPI (nuclei).
(E) Representative western blots from control and Spry2 cKO day-5 BCs showing SPRY2, pAKT, total AKT, pERK1/2, total ERK1/2, SOX2, and histone H3.
(F) Quantification of protein levels. Error bars denote SEM.
(G) Confocal images of control Tg(KRT5-CreER); Rosa26RfGFP/+ and cKO Tg(KRT5-CreER); Rosa26RfGFP/+; SpryD/fx tracheal sections at 1.5 weeks after tmx
administration showing an increase in pERK1/2 levels in the Spry2 cKO BCs. Green, GFP (reporter); red, pERK1/2 (active ERK1/2); blue, DAPI (nuclei).
Scale bars, 25 mm. See also Figure S3.
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Figure 7. Model of the Roles of FGFR1 and
SPRY2 in Airway Basal Cells
(A–C) Model for FGFR1-SPRY2 function in airway
BCs. (A) In wild-type BCs, FGFR1 signaling post-
translationally modifies SPRY2 resulting in an iso-
form of SPRY2 (red), which is able to inhibit ERK/
MAPK and AKT/PI3K signaling downstream of
other RTKs, such as EGFR. This FGFR1-SPRY2
signaling axis limits BC proliferation, resulting in
low levels of steady-state production of new cells.
(B) Following loss of FGFR1 there is amuch smaller
pool of ERK/AKT-inhibiting SPRY2 (red) and,
hence, more active ERK/MAPK and AKT/PI3K
signaling and greater levels of BC proliferation
and production of new basal and luminal cells. In
addition, the Fgfr1D/D cells cannot differentiate as
mature multi-ciliated cells due to a role for FGFR1
signaling in luminal fate choice. (C) Similarly,
following loss of all SPRY2 there is more active
ERK/MAPK and AKT/PI3K signaling and greater
levels of BC proliferation and, hence, production of
new basal and luminal cells. Moreover, a second
isoform of SPRY2 (orange), whichmay regulate the
level of EGFR protein, is also lost. However, FGFR1
is present and ciliated cell differentiation is normal.achieved complete recombination of the Spry2fx allele. In spite of
this there were large patches of GFP cells in our cultures that
had not recombined the Rosa reporter (Figure 6B). This indicates
that the Spry2fx allele recombines more efficiently than the
Rosa26R-fGFP reporter and supports the conclusion that most
of the GFP+ cells observed in vivo were co-recombinants with
Spry2fx. Therefore, it is likely that scoring GFP+ cells in the
Spry2 cKO tracheae results in a good approximation to the
Spry2D/D phenotype (compare with the Fgfr1 cKO tracheae,
where scoring GFP+ cells results in an underestimate of the
Fgfr1D/D phenotype).
The Spry2D/D cultures had a greater rate of proliferation than
the controls and also reached a higher cell density (Figures 6B
and 6C). Proliferation of the Spry2D/D cells slowed after the cells
reached confluence, but did continue (Figure 6C). Moreover,
confluent cultures could easily be passaged and continued to
show a faster proliferation rate (Figure 6D). Importantly, although
the Spry2D/D cells reached a greater density than controls, we
never observed phenotypes consistent with a complete loss of
contact inhibition, such as multi-layering or cell detachment.
This is again consistent with an altered threshold for, but not
complete loss of, contact inhibition.
Similar to the Fgfr1D/D cells, the Spry2D/D cells had a 3.5-fold
increase in pERK1/2 and a 5.2-fold increase in pAKT levels
compared with the controls (Figures 6E and 6F). These changes
were highly reproducible, although not always statistically signif-
icant. The increase in MAPK pathway activity was confirmed
in vivo by immunostaining for pERK1/2, which showed higher
levels in Spry2D/D BCs than controls at 1.5 weeks after tmx
administration (Figure 6G). We also observed that the Spry2D/D
cells had a 3.3-fold increase in levels of EGFR protein (Figures
6E and 6F). This is consistent with the published function of
the slower-migrating SPRY2 isoform (which is absent in the
Spry2D/D cells, but is unaffected in the Fgfr1D/D cells) in EGFR
trafficking/degradation (Gao et al., 2012; Kim et al., 2007; Walsh
and Lazzara, 2013).DISCUSSION
The tracheal epithelium is normally quiescent, with a minimal
amount of cell turnover. By combining in vivo genetic analysis
and primary cell culture, we have shown that BC proliferation
is actively repressed under steady-state conditions by an
FGFR1-SPRY2 signaling axis that functions to inhibit signaling
through the ERK and AKT intracellular pathways. This result
argues that airway quiescence does not result simply from the
absence of a proliferative signal or from feedback inhibitory
loops. Rather, we propose a model in which quiescence is
maintained by a balance between signaling mechanisms that
either promote proliferation or repress it. This is an emerging
theme in the stem cell biology of quiescent organs. For
example, a recent publication has found a similar tonic Hedge-
hog signal that inhibits steady-state proliferation in the smaller
mouse airways (Peng et al., 2015), but it is not known whether
this Hedgehog-based mechanism applies in the BC-containing
trachea.
SPRY2 was previously characterized in vitro as a protein
with two isoforms, which can either inhibit ERK/AKT signaling
(faster-migrating SPRY2 isoform) or modulate the subcellular
trafficking/degradation of EGFR protein (slower-migrating iso-
form) (Guy et al., 2009). However, the relative roles of these
SPRY2 isoforms in vivo and how they function downstream of
RTK receptors have not previously been explored. Several lines
of evidence presented here support a model in which the faster-
migrating SPRY2 functions downstream of FGFR1 to control
cell proliferation and tracheal epithelial homeostasis (Figure 7A).
First, following the loss of FGFR1 protein in airway BCs we
observe reduced levels of the faster-migrating (ERK/AKT-inhib-
iting) SPRY2 isoform, as well as increased levels of dpERK
and pAKT, increased rates of proliferation, and increased resis-
tance to EGFR inhibition. By contrast, the slower-migrating
SPRY2 isoform is unaffected (Figure 7B). Second, exposing
wild-type BCs to FGF2 ligand results in increased levels ofDevelopmental Cell 37, 85–97, April 4, 2016 93
faster-migrating SPRY2, a decrease in dpERK, and inhibition of
BC proliferation. Third, loss of all SPRY2 results in increased
ERK/AKT signaling and BC proliferation (Figure 7C). Taken
together, our data suggest that active FGFR1 signaling in the
steady-state trachea maintains a pool of SPRY2 protein, which
functions to antagonize ERK/AKT signaling and limit cell prolif-
eration downstream of other RTKs, most likely EGFR (Figure 7A).
A relationship between FGFR1 and post-translational modifica-
tion of SPRY2 protein has previously been documented in cell
lines in vitro (Lao et al., 2006, 2007). We now demonstrate its
importance in vivo, clearly illustrating that the context in which
a cell interprets EGFR/RTK signaling can be highly dependent
on the activity of other RTKs present. This has clear implications
for cancer development and the evolution of drug-resistant
tumors.
Another important finding of our work is that FGFR1 and
SPRY2 can also function independently in airway epithelial ho-
meostasis. FGFR1 is required formulti-ciliated cell differentiation
(Figure 4). Moreover, our data suggest that secretory cells are
produced at the expense of ciliated cells by the Fgfr1 cKO
BCs. A role for FGFR1 in ciliated cell differentiation is also consis-
tent with previous reports from other model organisms (Hong
and Dawid, 2009; Neugebauer et al., 2009), but the details of
the cellular requirements remain to be worked out. SPRY2 regu-
lates EGFR protein levels in BCs (Figure 6). Similar observations
have previously been made in vitro or in cancer models, but we
demonstrate this SPRY2-EGFR relationship for the first time in a
homeostatic tissue (Gao et al., 2012; Kim et al., 2007; Walsh and
Lazzara, 2013). SPRY2 thus emerges as a highly flexible switch
that can be modulated by FGFR1 signaling to control different
aspects of RTK signaling. In excess of ten phosphorylation sites
andmultiple binding partners have been documented for SPRY2
in vitro (DaSilva et al., 2006; Edwin et al., 2009; Lao et al., 2007).
These data suggest that SPRY2 is extensively and flexibly
modified in many different cellular settings in vivo and that our
observations may be the tip of the iceberg for the control of
cellular homeostasis by SPRY2.
A key question raised by our model concerns what activates
FGFR1 in vivo. We observed that FGF2 is transcribed in the
tracheal mesenchyme in vivo at steady state, and that recombi-
nant FGF2 inhibits tracheal BC proliferation and modulates
SPRY2 in vitro. These data are consistent with a role for FGF2
in activating FGFR1 signaling in vivo, although we note that other
FGF ligands are expressed in the steady-state airways. Interest-
ingly, in a recent screen of secreted proteins for their effect on
the ability of human airway BCs to form clonal organoids in cul-
ture, addition of FGF2 resulted in smaller tracheospheres with
fewer BCs (Danahay et al., 2015). This is highly consistent with
our in vitro results and suggests that a role for FGF2 signaling
in inhibiting airway BC proliferation is conserved betweenmouse
and humans.
Amplification of the FGFR1 locus, or increased levels of
FGFR1 protein, have been observed in 10%–20% of squamous
lung cancer cell lines, where FGFR1 has been implicated as a
driver mutation and putative therapeutic target (Dutt et al.,
2011; Weiss et al., 2010; Wynes et al., 2014). How do we recon-
cile this increase in FGFR1 expression in airway cancer with our
finding that an FGFR1-SPRY2 signaling module is required to
limit mouse airway BC proliferation at steady state? This will94 Developmental Cell 37, 85–97, April 4, 2016clearly require future investigation. However, the squamous
cell cancer lines used in these studies were isolated from the
end stage of a cancer development process and have under-
gone many genetic and epigenetic changes. Given the highly
context-dependent and cell-type-specific nature of FGFR1
signaling, and its interaction with SPRY2 and other RTKs as
we have observed, its function may change drastically during
neoplasia development. Nevertheless, we note that if a normal
function of FGFR1 signaling is to inhibit proliferation of wild-
type airway BCs, then it is possible that administration of
FGFR1-specific inhibitors as a cancer therapy may lead to clonal
expansion of other pre-malignant cells.
In conclusion, airway epithelial quiescence requires active
inhibition of proliferation by FGFR1 signaling, which results in
the post-translational modification of SPRY2 and inhibition of
signaling downstream of other RTKs, partly EGFR. We have
thus demonstrated a specific in vivo function for an FGFR1-
SPRY2 signaling axis that was previously documented in vitro.
This illustrates the complexity of RTK signaling networks and
the importance of further investigation in both homeostatic
tissues and developing malignancies.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for a full description of all
materials and methods used.
Mice
Experiments were performed under HomeOffice licenses PPL80/2326 and 70/
812. Fgfr1fx (Xu et al., 2002), Tg(KRT5-CreER) (Rock et al., 2009), Rosa26R-
fGFP (Rawlins et al., 2009), Spry2fx (Shim et al., 2005) were described previ-
ously. Fgfr1D/+ and Spry2D/+ were generated by crossing floxed alleles to
Zp3-Cre (de Vries et al., 2000). All strains weremaintained on a C57Bl/6J back-
ground. Males and females >8 weeks old were used. Wild-type mice were
C57Bl/6J.
Tamoxifen
Animals were injected intraperitoneally with tmx, 0.2 mg/g body weight, four
times every other day.
Tracheal Epithelial Cell Culture
Tracheae were cut into small pieces and incubated in 50% Dispase II (Gibco,
16 U/ml). Epithelial sheets were isolated and dissociated to single cells. Unless
otherwise stated, 5 3 104 cells in 0.5 ml of MTEC/+ medium (You et al., 2002)
were plated on collagen-coated 12-well tissue culture inserts (BD Falcon,
353180). Differentiation was induced in confluent cultures by removal of insert
medium and addition of MTEC serum-free medium to the outer chamber.
Ad-Cre (University of Iowa, Gene Transfer Vector Core) MOI 7 was used
for scattered recombination and MOI 2,500 for complete recombination;
1 3 106 vector plaque-forming units, 100 ng/ml recombinant mouse FGF2,
and 0.25 mM erlotinib (Sigma).
Immunostaining
Cryosections (6 mm) or whole-mount primary cultures were stained with
ACT (mouse, 1:3,000, Sigma, T7451), E-cadherin (rat, 1:3,000, Invitrogen,
13-1900), pERK1/2 (rabbit, 1:200, Cell Signaling Technology, 4695), FGFR1
(rabbit, 1:200, Novus Biologicals, NBP1-20067), FOXJ1 (mouse, 1:200,
eBioscience, clone 2A5, 14-9965-80), GFP (chick, 1:1,000, Abcam,
Ab13970), KRT5 (rabbit, 1:500, Covance, PRB-160P), KI67 (mouse, 1:200,
Becton Dickinson, 550609), SCGB1A1 (goat, 1:400, Santa Cruz Biotech-
nology, sc9772), SPRY2 (rabbit, 1:200, Abcam, Ab50317), and T1a (1:1,000,
DSHB, 8.1.1). Antigen retrieval was in 10 mM boiling sodium citrate for KI67
(pH 8), pERK1/2 (pH 6.5), and FOXJ1 (pH 6). Conjugated secondary
antibodies were Phalloidin-568 and Alexa Fluor (Life Technologies, 1:2,000).
mRNA In Situ Hybridization
Cryosections (10 mm) were hybridized with DIG-labeled anti-sense mRNA
probes to Fgfr1 (EST: AW495528) or Spry2 (Minowada et al., 1999) (DIG
RNA labeling kit, Roche, 11175025910), and visualized using alkaline phos-
phatase-coupled anti-DIG (1:2,000, Roche, 12930023) and BCIP/NBT (Roche,
1383213).
Microscopy and Image Scoring
Slides were imaged on a Zeiss AxioImager compound microscope or a Leica
Sp8/Sp5 confocal microscope as stated. Cells were scored manually in Fiji
(ImageJ), or using the Gurdon Institute Imaging Facility’s plugin ObjectScan.
For cryosections, every epithelial cell along the entire proximal to distal length
of a longitudinal section from the center of the trachea was scored. BCs were
T1a+ or KRT5+ with the apical surface not reaching the lumen. For cultured
cells, at least three random fields of view per insert were scored.
RT-PCR
Samples were enriched for epithelium or mesenchyme using Dispase diges-
tion and manual peeling. Total RNA was extracted using TRIzol reagent.
qRT-PCR
Primary tracheal epithelial cells were isolated and sorted using a fluorescence-
activated cell sorting MoFlo flow cytometer. Wild-type cells were gated as
basal EpCAM, GSIb4 lectin; secretory EpCAM, SSEA1; and ciliated EpCAM,
CD24. GFP+ BCs from control and Fgfr1 cKO tracheae were sorted as GFP,
GSIb4 lectin. Total RNA was extracted using a Qiagen RNEasy Mini Kit, and
Taqman gene expression assays (Life Technologies) were used.
Immunoblots
Cells were collected in Cell Extraction Buffer (Invitrogen, FNN0011) with
protease inhibitor (Roche, 04693116001) and PMSF (Sigma, P7626). Proteins
were separated on 10% or 12% SDS-PAGE gels before transfer to Millipore
Immobilon-P PVDF Membrane (Merck Millipore, IPVH00010). Membranes
were probed with pAKT(S473) (Cell Signaling, 3787, 1:3,000), pan-AKT (Cell
Signaling, 4691, 1:1,000), dpERK1/2 (Cell Signaling, 4370, 1:300), ERK1/2
(Cell Signaling, 4695, 1:300), SPRY2 (Abcam, Ab50317, 1:300), SOX2 (Abcam,
Ab97959, 1:3,000), Histone H3 (Abcam, Ab39655, 1:10,000), and EGFR
(Millipore, 04-290, 1:300). Detection was performed with horseradish peroxi-
dase-conjugated secondaries (Abcam, ab97051, ab97023, 1:10,000) and
enhanced chemiluminescence (Thermo Scientific, PI-32109). Quantitation is
based on analysis of protein from three biological replicates separated on
the same polyacrylamide gel. Band intensity was analyzed in Fiji normalized
to loading control.
Statistics
Statistics were calculated using Student’s two-tailed t test with unequal
variance.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.devcel.2016.03.001.
AUTHOR CONTRIBUTIONS
G.B. designed and performed experiments, analyzed data, and edited the
manuscript. J.J. performed experiments. M.A.B. provided mice and trachea
samples and assisted with experimental design. E.R. conceived and led the
project, performed experiments, analyzed data, and wrote and edited the
manuscript.
ACKNOWLEDGMENTS
This studywas supported by theMedical ResearchCouncil (G0900424 to E.R.)
and a Wellcome Trust clinical PhD fellowship (J.J.). Core grants: Gurdon Insti-
tute: Wellcome Trust (092096), Cancer Research UK (C6946/A14492); Stem
Cell Initiative: Wellcome Trust/MRC.Received: July 21, 2015
Revised: January 6, 2016
Accepted: March 1, 2016
Published: April 4, 2016
REFERENCES
Abler, L.L., Mansour, S.L., and Sun, X. (2009). Conditional gene inactivation
reveals roles for Fgf10 and Fgfr2 in establishing a normal pattern of epithelial
branching in the mouse lung. Dev. Dyn. 238, 1999–2013.
Arai, D., Hegab, A.E., Soejima, K., Kuroda, A., Ishioka, K., Yasuda, H., Naoki,
K., Kagawa, S., Hamamoto, J., Yin, Y., et al. (2015). Characterization of the cell
of origin and propagation potential of the fibroblast growth factor 9-induced
mouse model of lung adenocarcinoma. J. Pathol. 235, 593–605.
Blatt, E.N., Yan, X.H., Wuerffel, M.K., Hamilos, D.L., and Brody, S.L. (1999).
Forkhead transcription factor HFH-4 expression is temporally related to cilio-
genesis. Am. J. Respir. Cell Mol. Biol. 21, 168–176.
Brechbuhl, H.M., Li, B., Smith, R.W., and Reynolds, S.D. (2014). Epidermal
growth factor receptor activity is necessary for mouse basal cell proliferation.
Am. J. Physiol. Lung Cell Mol. Physiol. 307, L800–L810.
Chakkalakal, J.V., Jones, K.M., Basson, M.A., and Brack, A.S. (2012). The
aged niche disrupts muscle stem cell quiescence. Nature 490, 355–360.
Cole, B.B., Smith, R.W., Jenkins, K.M., Graham, B.B., Reynolds, P.R., and
Reynolds, S.D. (2010). Tracheal basal cells: a facultative progenitor cell pool.
Am. J. Pathol. 177, 362–376.
Danahay, H., Pessotti, A.D., Coote, J., Montgomery, B.E., Xia, D., Wilson, A.,
Yang, H., Wang, Z., Bevan, L., Thomas, C., et al. (2015). Notch2 is required
for inflammatory cytokine-driven goblet cell metaplasia in the lung. Cell Rep.
10, 239–252.
DaSilva, J., Xu, L., Kim, H.J., Miller, W.T., and Bar-Sagi, D. (2006). Regulation
of sprouty stability by Mnk1-dependent phosphorylation. Mol. Cell Biol. 26,
1898–1907.
de Vries, W.N., Binns, L.T., Fancher, K.S., Dean, J., Moore, R., Kemler, R., and
Knowles, B.B. (2000). Expression of Cre recombinase in mouse oocytes: a
means to study maternal effect genes. Genesis 26, 110–112.
Dutt, A., Ramos, A.H., Hammerman, P.S., Mermel, C., Cho, J., Sharifnia, T.,
Chande, A., Tanaka, K.E., Stransky, N., Greulich, H., et al. (2011). Inhibitor-
sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS
One 6, e20351.
Edwin, F., Anderson, K., Ying, C., and Patel, T.B. (2009). Intermolecular inter-
actions of Sprouty proteins and their implications in development and disease.
Mol. Pharmacol. 76, 679–691.
Gao, M., Patel, R., Ahmad, I., Fleming, J., Edwards, J., McCracken, S.,
Sahadevan, K., Seywright, M., Norman, J., Sansom, O., et al. (2012). SPRY2
loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and
mouse prostate carcinogenesis. EMBO Mol. Med. 4, 776–790.
Garmy-Susini, B., Delmas, E., Gourdy, P., Zhou, M., Bossard, C., Bugler, B.,
Bayard, F., Krust, A., Prats, A.C., Doetschman, T., et al. (2004). Role of fibro-
blast growth factor-2 isoforms in the effect of estradiol on endothelial cell
migration and proliferation. Circ. Res. 94, 1301–1309.
Giangreco, A., Lu, L., Vickers, C., Teixeira, V.H., Groot, K.R., Butler, C.R.,
Ilieva, E.V., George, P.J., Nicholson, A.G., Sage, E.K., et al. (2012). Beta-cat-
enin determines upper airway progenitor cell fate and preinvasive squamous
lung cancer progression by modulating epithelial-mesenchymal transition.
J. Pathol. 226, 575–587.
Guy, G.R., Jackson, R.A., Yusoff, P., and Chow, S.Y. (2009). Sprouty proteins:
modified modulators, matchmakers or missing links? J. Endocrinol. 203,
191–202.
Hackett, N.R., Shaykhiev, R., Walters, M.S., Wang, R., Zwick, R.K., Ferris, B.,
Witover, B., Salit, J., and Crystal, R.G. (2011). The human airway epithelial
basal cell transcriptome. PLoS One 6, e18378.
Hadjab, S., Franck, M.C., Wang, Y., Sterzenbach, U., Sharma, A., Ernfors, P.,
and Lallemend, F. (2013). A local source of FGF initiates development of the
unmyelinated lineage of sensory neurons. J. Neurosci. 33, 17656–17666.Developmental Cell 37, 85–97, April 4, 2016 95
Hogan, B.L., Barkauskas, C.E., Chapman, H.A., Epstein, J.A., Jain, R., Hsia,
C.C., Niklason, L., Calle, E., Le, A., Randell, S.H., et al. (2014). Repair and
regeneration of the respiratory system: complexity, plasticity, and mecha-
nisms of lung stem cell function. Cell Stem Cell 15, 123–138.
Hong, S.K., and Dawid, I.B. (2009). FGF-dependent left-right asymmetry
patterning in zebrafish is mediated by Ier2 and Fibp1. Proc. Natl. Acad. Sci.
USA 106, 2230–2235.
Hong, K.U., Reynolds, S.D., Watkins, S., Fuchs, E., and Stripp, B.R. (2004).
In vivo differentiation potential of tracheal basal cells: evidence for multipotent
and unipotent subpopulations. Am. J. Physiol. Lung Cell Mol. Physiol. 286,
L643–L649.
Huang, T., You, Y., Spoor, M.S., Richer, E.J., Kudva, V.V., Paige, R.C., Seiler,
M.P., Liebler, J.M., Zabner, J., Plopper, C.G., et al. (2003). Foxj1 is required
for apical localization of ezrin in airway epithelial cells. J. Cell Sci. 116, 4935–
4945.
Kauffman, S.L. (1980). Cell proliferation in the mammalian lung. Int. Rev. Exp.
Pathol. 22, 131–191.
Kim, H.J., Taylor, L.J., and Bar-Sagi, D. (2007). Spatial regulation of EGFR
signaling by Sprouty2. Curr. Biol. 17, 455–461.
Kranenburg, A.R., Willems-Widyastuti, A., Mooi, W.J., Saxena, P.R., Sterk,
P.J., de Boer, W.I., and Sharma, H.S. (2005). Chronic obstructive pulmonary
disease is associated with enhanced bronchial expression of FGF-1, FGF-2,
and FGFR-1. J. Pathol. 206, 28–38.
Lao, D.H., Chandramouli, S., Yusoff, P., Fong, C.W., Saw, T.Y., Tai, L.P., Yu,
C.Y., Leong, H.F., and Guy, G.R. (2006). A Src homology 3-binding sequence
on the C terminus of Sprouty2 is necessary for inhibition of the Ras/
ERK pathway downstream of fibroblast growth factor receptor stimulation.
J. Biol. Chem. 281, 29993–30000.
Lao, D.H., Yusoff, P., Chandramouli, S., Philp, R.J., Fong, C.W., Jackson, R.A.,
Saw, T.Y., Yu, C.Y., and Guy, G.R. (2007). Direct binding of PP2A to Sprouty2
and phosphorylation changes are a prerequisite for ERK inhibition down-
stream of fibroblast growth factor receptor stimulation. J. Biol. Chem. 282,
9117–9126.
Lu, L., Teixeira, V.H., Yuan, Z., Graham, T.A., Endesfelder, D., Kolluri, K.,
Al-Juffali, N., Hamilton, N., Nicholson, A.G., Falzon, M., et al. (2013). LRIG1
regulates cadherin-dependent contact inhibition directing epithelial homeo-
stasis and pre-invasive squamous cell carcinoma development. J. Pathol.
229, 608–620.
Mahoney, J.E., Mori, M., Szymaniak, A.D., Varelas, X., and Cardoso, W.V.
(2014). The hippo pathway effector Yap controls patterning and differentiation
of airway epithelial progenitors. Dev. Cell 30, 137–150.
Minowada, G., Jarvis, L.A., Chi, C.L., Neubuser, A., Sun, X., Hacohen, N.,
Krasnow,M.A., andMartin, G.R. (1999). Vertebrate Sprouty genes are induced
by FGF signaling and can cause chondrodysplasia when overexpressed.
Development 126, 4465–4475.
Mori, M., Mahoney, J.E., Stupnikov, M.R., Paez-Cortez, J.R., Szymaniak, A.D.,
Varelas, X., Herrick, D.B., Schwob, J., Zhang, H., and Cardoso, W.V. (2015).
Notch3-Jagged signaling controls the pool of undifferentiated airway progen-
itors. Development 142, 258–267.
Neugebauer, J.M., Amack, J.D., Peterson, A.G., Bisgrove, B.W., and Yost,
H.J. (2009). FGF signalling during embryo development regulates cilia length
in diverse epithelia. Nature 458, 651–654.
Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F.,
Gao, G., and Goldfarb, M. (1996). Receptor specificity of the fibroblast growth
factor family. J. Biol. Chem. 271, 15292–15297.
Pardo-Saganta, A., Law, B.M., Tata, P.R., Villoria, J., Saez, B., Mou, H., Zhao,
R., and Rajagopal, J. (2015). Injury induces direct lineage segregation of func-
tionally distinct airway basal stem/progenitor cell subpopulations. Cell Stem
Cell 16, 184–197.
Paul, M.K., Bisht, B., Darmawan, D.O., Chiou, R., Ha, V.L., Wallace, W.D.,
Chon, A.T., Hegab, A.E., Grogan, T., Elashoff, D.A., et al. (2014). Dynamic
changes in intracellular ROS levels regulate airway basal stem cell homeosta-
sis through Nrf2-dependent notch signaling. Cell Stem Cell 15, 199–214.96 Developmental Cell 37, 85–97, April 4, 2016Peng, T., Frank, D.B., Kadzik, R.S., Morley, M.P., Rathi, K.S., Wang, T., Zhou,
S., Cheng, L., Lu, M.M., and Morrisey, E.E. (2015). Hedgehog actively main-
tains adult lung quiescence and regulates repair and regeneration. Nature
526, 578–582.
Rawlins, E.L., and Hogan, B.L. (2008). Ciliated epithelial cell lifespan in the
mouse trachea and lung. Am. J. Physiol. Lung Cell Mol. Physiol. 295, L231–
L234.
Rawlins, E.L., Ostrowski, L.E., Randell, S.H., and Hogan, B.L. (2007). Lung
development and repair: contribution of the ciliated lineage. Proc. Natl.
Acad. Sci. USA 104, 410–417.
Rawlins, E.L., Okubo, T., Xue, Y., Brass, D.M., Auten, R.L., Hasegawa, H.,
Wang, F., and Hogan, B.L. (2009). The role of Scgb1a1+ Clara cells in the
long-term maintenance and repair of lung airway, but not alveolar, epithelium.
Cell Stem Cell 4, 525–534.
Rock, J.R., Onaitis, M.W., Rawlins, E.L., Lu, Y., Clark, C.P., Xue, Y., Randell,
S.H., and Hogan, B.L. (2009). Basal cells as stem cells of the mouse trachea
and human airway epithelium. Proc. Natl. Acad. Sci. USA 106, 12771–
12775.
Rock, J.R., Randell, S.H., and Hogan, B.L. (2010). Airway basal stem cells:
a perspective on their roles in epithelial homeostasis and remodeling. Dis.
Model. Mech. 3, 545–556.
Rock, J.R., Gao, X., Xue, Y., Randell, S.H., Kong, Y.Y., and Hogan, B.L. (2011).
Notch-dependent differentiation of adult airway basal stem cells. Cell Stem
Cell 8, 639–648.
Rubin, C., Zwang, Y., Vaisman, N., Ron, D., and Yarden, Y. (2005).
Phosphorylation of carboxyl-terminal tyrosines modulates the specificity
of Sprouty-2 inhibition of different signaling pathways. J. Biol. Chem. 280,
9735–9744.
Shea, K.L., Xiang, W., LaPorta, V.S., Licht, J.D., Keller, C., Basson, M.A., and
Brack, A.S. (2010). Sprouty1 regulates reversible quiescence of a self-
renewing adult muscle stem cell pool during regeneration. Cell Stem Cell 6,
117–129.
Shim, K., Minowada, G., Coling, D.E., and Martin, G.R. (2005). Sprouty2,
a mouse deafness gene, regulates cell fate decisions in the auditory sensory
epithelium by antagonizing FGF signaling. Dev. Cell 8, 553–564.
Teixeira, V.H., Nadarajan, P., Graham, T.A., Pipinikas, C.P., Brown, J.M.,
Falzon, M., Nye, E., Poulsom, R., Lawrence, D., Wright, N.A., et al. (2013).
Stochastic homeostasis in human airway epithelium is achieved by neutral
competition of basal cell progenitors. Elife 2, e00966.
Vermeer, P.D., Einwalter, L.A., Moninger, T.O., Rokhlina, T., Kern, J.A.,
Zabner, J., and Welsh, M.J. (2003). Segregation of receptor and ligand regu-
lates activation of epithelial growth factor receptor. Nature 422, 322–326.
Volckaert, T., Dill, E., Campbell, A., Tiozzo, C., Majka, S., Bellusci, S., and
De Langhe, S.P. (2011). Parabronchial smooth muscle constitutes an airway
epithelial stem cell niche in the mouse lung after injury. J. Clin. Invest. 121,
4409–4419.
Volckaert, T., Campbell, A., Dill, E., Li, C., Minoo, P., and De Langhe, S. (2013).
Localized Fgf10 expression is not required for lung branching morphogenesis
but prevents differentiation of epithelial progenitors. Development 140, 3731–
3742.
Walsh, A.M., and Lazzara, M.J. (2013). Regulation of EGFR trafficking and
cell signaling by Sprouty2 and MIG6 in lung cancer cells. J. Cell Sci. 126,
4339–4348.
Watson, J.K., Rulands, S., Wilkinson, A.C., Wuidart, A., Ousset, M., Van
Keymeulen, A., Gottgens, B., Blanpain, C., Simons, B.D., and Rawlins, E.L.
(2015). Clonal dynamics reveal two distinct populations of basal cells in
slow-turnover airway epithelium. Cell Rep. 12, 90–101.
Weiss, J., Sos, M.L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J.M.,
Ullrich, R.T., Menon, R., Maier, S., Soltermann, A., et al. (2010). Frequent
and focal FGFR1 amplification associates with therapeutically tractable
FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2, 62ra93.
Wynes, M.W., Hinz, T.K., Gao, D., Martini, M., Marek, L.A., Ware, K.E.,
Edwards, M.G., Bohm, D., Perner, S., Helfrich, B.A., et al. (2014). FGFR1
mRNA and protein expression, not gene copy number, predict FGFR TKI
sensitivity across all lung cancer histologies. Clin. Cancer Res. 20, 3299–3309.
Xu, X., Qiao, W., Li, C., and Deng, C.X. (2002). Generation of Fgfr1 conditional
knockout mice. Genesis 32, 85–86.
Yin, Y., Wang, F., and Ornitz, D.M. (2011). Mesothelial- and epithelial-derived
FGF9 have distinct functions in the regulation of lung development.
Development 138, 3169–3177.You, Y., Richer, E.J., Huang, T., and Brody, S.L. (2002). Growth and differen-
tiation of mouse tracheal epithelial cells: selection of a proliferative population.
Am. J. Physiol. Lung Cell Mol. Physiol. 283, L1315–L1321.
Zhao, R., Fallon, T.R., Saladi, S.V., Pardo-Saganta, A., Villoria, J., Mou, H.,
Vinarsky, V., Gonzalez-Celeiro, M., Nunna, N., Hariri, L.P., et al. (2014). Yap
tunes airway epithelial size and Architecture by regulating the identity, mainte-
nance, and self-Renewal of stem cells. Dev. Cell 30, 151–165.Developmental Cell 37, 85–97, April 4, 2016 97
